Raf/MEK/Erk inhibitors (Lee Moffitt Cancer Center)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameRaf/MEK/Erk inhibitors (Lee Moffitt Cancer Center)
Drug Alias NameERK1-624ERK1-23211ERK1-2067
ClassificationBiologics
Mechanisms of ActionMitogen-activated protein kinase; ERK1/ERK2 inhibitorsRAF serine/threonine protein kinase inhibitorsDual specificity mitogen-activated protein kinase kinase inhibitors +[4] 
TargetsDual specificity mitogen-activated protein kinase kinaseMitogen-activated protein kinase; ERK1/ERK2RAF serine/threonine protein kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesH Lee Moffitt Cancer Center & Research Institute
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A